C4 Therapeutics Inc

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3 (IKZF1/3) for multiple myeloma, which has completed phase 1. The company is also developing CFT8919, an orally bioavailable, allosteric, mutant-selective bidac degrader of epidermal growth factor receptor with the L858R mutation in non-small cell lung cancer, as well as new degraders focused on inflammation, neuroinflammation, and neurodegeneration. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc., Betta Pharmaceuticals Co. Ltd., and Merck KGaA, and a collaboration agreement with Roche Holding AG for the development of Degrader-Antibody Conjugates for cancer treatment. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.